Sputnik V Vaccine Elicits Seroconversion and Neutralizing Capacity to SARS CoV-2 after a Single Dose

ANDRES H. ROSSI; DIEGO S. OJEDA; AUGUSTO VARESE; LAUTARO SÁNCHEZ; MARÍA MORA GONZÁLES LÓPEZ LEDESMA; IGNACIO MAZZITELLI; ANABEL ÁLVAREZ JULIA; SANTIAGO OVIEDO ROUCO; HORACIO M. PALLARÉS; GUADALUPE COSTA NAVARRO; NATALÍ RASETTO; CORINA I. GARCÍA; SHIRLEY D. WENKER; LILA Y. RAMIS; MAGALÍ G. BIALER; MARÍA JOSÉ DE LEONE; ESTEBAN HERNANDO; SANTIAGO SOSA; LUCIANA BIANCHIMANO; ANTONELLO RÍOS; MARÍA SOLEDAD TREFFINGER CIENFUEGOS; JULIO J. CARAMELO; YÉSICA LONGUERIA; NATALIA LAUFER; DIEGO ÁLVAREZ; JORGE CARRADORI; NICOLÁS KREPLAK; MARCELO YANOVSKY; JORGE GEFFNER; MARINA PIFANO; ANDREA V. GAMARNIK

Cell reports medicine

Cell Press

Año: 2021

2666-3791

Massive vaccination offers great promise for halting the global COVID-19 pandemic. However, limited supply and uneven vaccine distribution create an urgent need to optimize vaccination strategies. We evaluate SARS-CoV-2-specific antibody responses after Sputnik V vaccination of healthcare workers in Argentina, measuring IgG anti-spike titers and neutralizing capacity after one and two doses in a cohort of naïve or previously infected volunteers. By 21 days after receiving the first dose of vaccine, 94% of naïve participants develop spike-specific IgG antibodies. A single Sputnik V dose elicits higher antibody levels and virus neutralizing capacity in previously infected individuals than in naïve ones receiving the full two-dose schedule. The high seroconversion rate after a single dose in naïve participants suggests a benefit of delaying second dose administration to increase the number of people vaccinated. The data presented provide information for guiding public health decisions in light of the current global health emergency.